Creating a World Class Platform JP Morgan Healthcare Conference Presentation January 2026 © 2026 AtriCure, Inc. All rights reserved. Forward Looking Statements and Non-GAAP Financial Measures This presentation and oral statements made in connection with this presentation contain "forward-looking statements," which are statements related to future events that by their nature address matters that are uncertain. Forward-looking statements address, among other things, AtriCure's expected market opportunity, gui ...

第21批援圭亚那中国医疗队中医科近日参与乔治敦公立医院疼痛联合门诊，探索中医药与现代医学协同诊疗新模式，围绕疼痛管理、功能恢复及合理用药 开展实践，为当地患者提供更多安全、有效的治疗选择。 扬子晚报/紫牛新闻记者吕彦霖 在近期一次联合门诊中，中医科医生魏浩洋接诊一名足底筋膜炎患者，该患者行走跛行，就诊时疼痛评分达9分。按原有流程，患者开具镇痛药物后需再 次预约后续物理治疗。魏浩洋在与团队沟通后，现场采用"筋针"疗法进行治疗。进针后患者疼痛明显缓解，评分降至4分，行走能力显著改善。使患者在 本次就诊中就能看到立竿见影的效果。 "筋针"是一种融合传统针灸与现代软组织损伤学说的针刺疗法，主要用于肌筋膜疼痛等"筋病"，具有浅刺、起效快、刺激轻等特点，有助于减少患者在等 待期间对镇痛药物的依赖。接受本次治疗的患者表示，首次接触针灸即感过程舒适、效果明显，第一次体验到中医的神奇，并主动预约后续治疗。 通讯员李妍雨 医疗队队长李欢送表示，中医中药治疗在疼痛管理与功能恢复方面具有独特优势。参与联合门诊不仅为患者提供了多元化、非药物的治疗选择，也为当地 医务人员了解中医提供了实践平台。下一步，医疗队将持续参与临床诊疗，并通过技 ...

Problem & Impact - Clinically important research findings take an average of 17 years to translate into widespread healthcare practice, often not happening at all [1] - This delay is a source of frustration, especially concerning vulnerable populations like older adults with dementia who may not live long enough to benefit from current solutions [2] - Up to 80% of older adults with dementia suffer from pain, which is often under-recognized, under-detected, and under-treated due to communication difficulties [3] - Undertreated pain in dementia patients can lead to challenging responsive behaviors, often misattributed to psychiatric causes and treated with psychotropic medication, which can hasten death [5][6] - The aging population will exacerbate the problem, with projections indicating that 20% of the Canadian population is currently 65 years or older, and this will increase to one in four within 45 years [11] - This demographic shift will lead to an increase in dementia cases, with projections of 17 million Canadians and 127 million Americans living with dementia in 25 years [12] Proposed Solution & Results - Systematic observation and recording of specific pain behaviors can improve pain recognition and evaluation in dementia patients [7] - Frequent pain assessment improves quality of care, quality of life, and reduces stress for nursing staff [8] - Traditional methods of disseminating research findings (seminars, webinars, brochures) are not very effective in changing clinical practices and patient outcomes [9][10] - Social media campaigns, inspired by examples like Christine Chambers' pediatric pain management campaign (100 million impressions, 150,000 YouTube views), can increase public awareness and potentially impact policy [16][17] - A social media campaign focused on pain in dementia achieved 55 million impressions and 50,000 YouTube views in five months, doubling the conversation about pain and dementia on Twitter [21][23] - While social media doesn't completely solve the problem, it positions researchers to narrow the 17-year gap by reaching millions of people and facilitating interaction [29]

Core Viewpoint - NeuroOne Medical Technologies Corporation has received FDA clearance for its OneRF Trigeminal Nerve Ablation System, which offers a minimally invasive alternative for treating trigeminal neuralgia, a chronic pain condition affecting approximately 150,000 people annually in the U.S. [1][2] Group 1: Product and Technology - The OneRF Trigeminal Nerve Ablation System utilizes a proprietary RF generator platform to create radiofrequency lesions for pain treatment and functional neurosurgical procedures [1][2] - This system features a unique multi-contact RF probe that allows for precise localization and tailored ablation of nerve tissue, enhancing safety and accuracy during procedures [3] - The technology aims to reduce procedural time, improve patient comfort, and enhance overall patient safety [3] Group 2: Market Potential and Strategy - The company plans a limited commercial launch of the OneRF system in the fourth quarter of 2025, with expectations to generate revenues from trigeminal nerve ablation by late 2025 [1][4] - NeuroOne's technology platform has potential applications across various neurological disorders and pain management functions, including lower back pain [4] - Current users of the OneRF brain ablation system may also adopt the nerve ablation procedures, justifying further investment in the technology [4] Group 3: Company Overview - NeuroOne Medical Technologies Corporation focuses on developing minimally invasive solutions for various neurological disorders, including epilepsy and chronic pain [5] - The company is exploring additional therapeutic applications, such as treatments for depression, mood disorders, and high blood pressure [5]

Cancer Care Crisis & Communication Breakdown - The cancer care system faces a communication crisis leading to unnecessary patient suffering [1] - Up to 70% of cancer patients don't disclose their use of integrative therapies due to fear [1] - While up to 66% of oncologists believe integrative approaches are beneficial, many hesitate to discuss them due to time constraints, limited training, and uncertainty about the evidence [1] Integrative Oncology & Its Benefits - Integrative oncology, using evidence-based practices like acupuncture, massage, meditation, and yoga alongside conventional treatments, can empower patients [1] - Integrative oncology improves well-being and quality of life in up to 65% of patients [2] - Hospitals with integrative oncology involvement have improved five-year overall survival odds [2] Call to Action & Solutions - Implementing structured conversations about integrative oncology at diagnosis is crucial [2] - Training oncologists to discuss pain management, emotional well-being, and whole-person care is essential [2] - Healthcare providers should utilize existing clinical guidelines from ASCO and the Society of Integrative Oncology to manage side effects [2]

As filed with the Securities and Exchange Commission on November 7, 2023 Registration No. 333-269188 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 8 to FORM S-1 REGISTRATION STATEMENT under The Securities Act of 1933 CHROMOCELL THERAPEUTICS CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2836 86-3335449 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Id ...

As filed with the Securities and Exchange Commission on October 13, 2023 Registration No. 333-269188 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 6 to FORM S-1 REGISTRATION STATEMENT under The Securities Act of 1933 CHROMOCELL THERAPEUTICS CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2836 86-3335449 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Id ...

As filed with the Securities and Exchange Commission on September 1, 2023 Registration No. 333-269188 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 5 to FORM S-1 REGISTRATION STATEMENT under The Securities Act of 1933 CHROMOCELL THERAPEUTICS CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2836 86-3335449 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer I ...

As filed with the Securities and Exchange Commission on June 30, 2023 Registration No. 333-269188 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 to FORM S-1 REGISTRATION STATEMENT under The Securities Act of 1933 CHROMOCELL THERAPEUTICS CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2836 86-3335449 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Ident ...

As filed with the Securities and Exchange Commission on May 1, 2023 Registration No. 333-269188 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT under The Securities Act of 1933 CHROMOCELL THERAPEUTICS CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2836 86-3335449 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identif ...